T5O Stock Overview
bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
bioXXmed AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.47 |
| 52 Week High | €2.34 |
| 52 Week Low | €0.30 |
| Beta | 1.2 |
| 1 Month Change | 56.67% |
| 3 Month Change | -14.55% |
| 1 Year Change | -79.20% |
| 3 Year Change | -97.27% |
| 5 Year Change | -95.41% |
| Change since IPO | -96.75% |
Recent News & Updates
Shareholder Returns
| T5O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -4.9% | -1.5% |
| 1Y | -79.2% | -19.9% | 0.9% |
Return vs Industry: T5O underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: T5O underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| T5O volatility | |
|---|---|
| T5O Average Weekly Movement | 27.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: T5O's share price has been volatile over the past 3 months.
Volatility Over Time: T5O's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1 | Mark-André Freyberg | cytotools.de |
bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022.
bioXXmed AG Fundamentals Summary
| T5O fundamental statistics | |
|---|---|
| Market cap | €2.41m |
| Earnings (TTM) | -€660.70k |
| Revenue (TTM) | €20.51k |
117.7x
P/S Ratio-3.7x
P/E RatioIs T5O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T5O income statement (TTM) | |
|---|---|
| Revenue | €20.51k |
| Cost of Revenue | €0 |
| Gross Profit | €20.51k |
| Other Expenses | €681.22k |
| Earnings | -€660.70k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,220.75% |
| Debt/Equity Ratio | 0% |
How did T5O perform over the long term?
See historical performance and comparison